Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020114390 - Nanoparticle Delivery System

Publication Number WO/2020/114390
Publication Date 11.06.2020
International Application No. PCT/CN2019/122687
International Filing Date 03.12.2019
IPC
A61K 47/68 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/64 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/54 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
54the modifying agent being an organic compound
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • MASTER DYNAMIC LIMITED [CN]/[CN]
Inventors
  • CHENG, Ka Wing
  • HUI, Koon Chung
  • KONG, Ching Tom
Agents
  • CHINA SINDA INTELLECTUAL PROPERTY LIMITED
Priority Data
18115449.503.12.2018HK
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) Nanoparticle Delivery System
(FR) SYSTÈME D'ADMINISTRATION DE NANOPARTICULES
Abstract
(EN)
A conjugate(110) comprising a nanoparticle(210) for delivery of a drug to a treatment site in the body of a subject; a drug molecule(220) releasably linked to said nanoparticle(210), wherein said drug molecule(220) has a therapeutic effect at the treatment site in the body of the subject; and a disease targeting molecule(230) releasably linked to said nanoparticle(210); wherein upon said conjugate(110) being adjacent diseased tissue(240) of a subject, said disease targeting molecule(230) retains the conjugate(110) adjacent said diseased tissue(240); said drug molecule(220) is released from said nanoparticle(110) so as to provide a therapeutic effect to said diseased tissue(240); and said disease targeting molecule(230) is subsequently released from said nanoparticle(210) such that retention of the nanoparticle(210) is released, and such that the nanoparticle(210) is dispersible from said diseased tissue(240).
(FR)
L'invention concerne un conjugué (110) comprenant une nanoparticule (210), destiné à l'administration d'un médicament sur un site de traitement dans le corps d'un sujet ; une molécule de médicament (220) est liée de manière réversible à ladite nanoparticule (210), ladite molécule de médicament (220) ayant un effet thérapeutique sur le site de traitement dans le corps du sujet ; et une molécule de ciblage de maladie (230) est liée de manière réversible à ladite nanoparticule (210) ; quand ledit conjugué (110) est adjacent à un tissu malade (240) d'un sujet, ladite molécule de ciblage de maladie (230) retenant le conjugué (110) adjacent audit tissu malade (240) ; ladite molécule de médicament (220) est libérée de ladite nanoparticule (110) de manière à fournir un effet thérapeutique audit tissu malade (240) ; et ladite molécule de ciblage de maladie (230) est ensuite libérée de ladite nanoparticule (210), de sorte que la rétention de la nanoparticule (210) soit libérée et que la nanoparticule (210) soit dispersible à partir dudit tissu malade (240).
Latest bibliographic data on file with the International Bureau